Near future
Contacts
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
May 23, 2022

Coronavirus / Russia-Ukraine

Near future

News to understand, anticipate, improve the future.

No Result
View All Result

News to understand, anticipate, improve the future.

Read in:  Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

Tirzepatide, remarkable tests: average weight loss of 24kg. Goodbye obesity?

Patients with obesity from a large clinical trial lost an average of 24kg when treated with the highest dose of a new hunger-blocking drug

Gianluca Ricciodi Gianluca Riccio
in Medicine
Share77Pin18Tweet48SendShare14ShareShare10
61B51597 103B 441B 8445 532A1CEA5916
May 6, 2022
⚪ Reads in 3 minutes
A A

Tirzepatide has shown incredible results in clinical trials. On average, patients who received it as a treatment lost 24 kg during the study period. It can be a giant step forward in the treatment of obesity, helping millions of people around the world lose weight.

A drug instead of surgery?

In fact, the weight loss achieved in the tests is surprising - it is the equivalent of a bariatric surgery. Is it plausible that tirzepatide could replace surgery in the treatment of obesity in the near future?

The drug combines synthetic imitations of two hormones known as GLP-1 e GIP, that our body releases naturally when we eat, to provide us with the feeling of satiety.

Maybe you are also interested

US researchers create the 'multi-organ' chip to test the effect of drugs

3D printed medicines in seven seconds

Plug & Play, wearable injector that makes biological drugs always active

New drug can prevent metastasis by 'putting cancer cells to sleep'

Tirzepatide obesity
A model of the GLP-1 hormone, which Tirzepatide "mimics".

In an advanced clinical trial, over 2.500 individuals in nine countries received weekly injections of low, medium, or high-dose tirzepatide (or a placebo) for 72 weeks.

Patients who received the highest dose had an average weight loss of 24 kilograms. Almost a quarter of the body weight. In comparison, participants taking the placebo lost only 2 kilograms on average. The results have been announced from the US pharmaceutical giant Lilly, which is developing the drug.

Obesity is a fight without quarter

The pharmacological approach to obesity does not start today. As early as June 2021, the American FDA had approved another drug called semaglutide which contains only the GLP-1 hormone, without the addition of GIP. The results? Good, with an average weight loss of 15%, but the newly developed drug is much more advanced.

For both drugs, however, there are contraindications: side effects such as nausea, vomiting, diarrhea and constipation (which seem to get worse at higher doses). The experience gained with semaglutide suggest that starting with low doses and gradually increasing them can avoid these side effects.

The advantages are undoubted

To be clear: these obesity drugs can be discontinued, bariatric surgery cannot. You can never have a normal or large meal again, even on a special occasion. Of course, it is also true that surgery is done only once, while these drugs must be taken continuously.

Let's put it this way: it is imperative that people have many options for acting on obesity. Now another 104 weeks of monitoring (to determine if tirzepatide also prevents type 2 diabetes, but more on that) and then Lilly will ask for approval of the drug.

Obesity is a global problem and we need to more effective treatments than ever. Tirzepatide could be the decisive step.

tags: drugsobesity
Previous post

Top of the Rock, the fantastic attractions on the "telescopic" roof in New York

Next Post

T'ROI and the simple things that change the world

COLLABORATE

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff
  • Domus trimaran

    Domus, crazy zero-emission trimaran

    12514 Shares
    Share 5003 Tweet 3127
  • ETH technology: drinking water from the air 24 hours a day, without power supply

    7916 Shares
    Share 3165 Tweet 1978
  • Vaxinia, first patient receives oncolytic virus that kills cancer

    2192 Shares
    Share 876 Tweet 548
  • University of Maryland, new study: there would be a reality beyond this

    2032 Shares
    Share 812 Tweet 508
  • Hermeus tries it: hypersonic planes of 6000 kilometers per hour

    2829 Shares
    Share 1131 Tweet 707

archive

Have a look here:

Technology

Blue Abyss, the deepest indoor abyss pool in the world

An indoor abyss: Blue Abyss is a 50 meters deep backdrop made in an indoor structure. Good idea,...

Read More
Future Mobility Concept

Future Mobility Concept, between recumbent bicycle and car: will we move like this?

Goodbye needles: LUMI, the oral capsules with microneedles are the new injections

energy floor

PaveGen, the intelligent wooden floor that produces energy

Coronavirus, China sprays entire neighborhoods of disinfectants

Next Post
1 1

T'ROI and the simple things that change the world

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Subscribe to our newsletter

Environment
Architecture
Artificial intelligence
Gadgets
concepts
Design

Staff
Archives
Advertising
Privacy Policy

Medicine
Spazio
Robotica
Work
Transportation
energia

To contact the FuturoProssimo editorial team, write to redazione@futuroprossimo.it

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

The daily tomorrow

Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

Chinese Version
Édition Française
Deutsche Ausgabe
Japanese version
English Edition
Edição Portuguesa
Русское издание
Spanish edition

Staff
Archives
Advertising
Privacy Policy

Subscribe to our newsletter

To contact the FuturoProssimo editorial team, write to redazione@futuroprossimo.it

Categories

This work is distributed under license Creative Commons Attribution 4.0 International.
© 2021 Futuroprossimo

No Result
View All Result
  • Home
  • Tech
  • Health
  • Environment
  • Architecture
  • energia
  • Transportation
  • Spazio
  • AI
  • concepts
  • Gadgets
  • Italy Next
  • H+
This site uses cookies. By continuing to read it, you consent to their use.